Genetic Predisposition to Schizophrenia and Depressive Disorder Comorbidity.

Autor: Shnayder NA; Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.; Shared Core Facilities 'Molecular and Cell Technologies', V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia., Novitsky MA; Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia., Neznanov NG; Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.; Department of Psychiatry and Addiction, I.M. Pavlov First Saint Petersburg State Medical University, 197022 Saint Petersburg, Russia., Limankin OV; P.P. Kashchenko Saint Petersburg Psychiatric Hospital No. 1, Gatchinsky District, 190005 Leningrad, Russia.; Department of Psychotherapy and Sexual Medicine, I.I. Mechnikov North-Western State University, 191015 Saint Petersburg, Russia.; Department of Social Psychiatry and Psychology, Saint Petersburg Postgraduate Institute of Medical Experts, 194044 Saint Petersburg, Russia., Asadullin AR; Department of Psychiatry and Addiction, Bashkir State Medical University, 450008 Ufa, Russia., Petrov AV; Shared Core Facilities 'Molecular and Cell Technologies', V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia., Dmitrenko DV; Shared Core Facilities 'Molecular and Cell Technologies', V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia., Narodova EA; Shared Core Facilities 'Molecular and Cell Technologies', V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia., Popenko NV; Shared Core Facilities 'Molecular and Cell Technologies', V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia., Nasyrova RF; Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.; International Centre for Education and Research in Neuropsychiatry, Samara State Medical University, 443099 Samara, Russia.
Jazyk: angličtina
Zdroj: Genes [Genes (Basel)] 2022 Mar 02; Vol. 13 (3). Date of Electronic Publication: 2022 Mar 02.
DOI: 10.3390/genes13030457
Abstrakt: Background : Patients with schizophrenia have an increased risk of depressive disorders compared to the general population. The comorbidity between schizophrenia and depression suggests a potential coincidence of the pathophysiology and/or genetic predictors of these mental disorders. The aim of this study was to review the potential genetic predictors of schizophrenia and depression comorbidity. Materials and Methods : We carried out research and analysis of publications in the databases PubMed, Springer, Wiley Online Library, Taylor & Francis Online, Science Direct, and eLIBRARY.RU using keywords and their combinations. The search depth was the last 10 years (2010-2020). Full-text original articles, reviews, meta-analyses, and clinical observations were analyzed. A total of 459 articles were found, of which 45 articles corresponding to the purpose of this study were analyzed in this topic review. Results : Overlap in the symptoms and genetic predictors between these disorders suggests that a common etiological mechanism may underlie the presentation of comorbid depression in schizophrenia. The molecular mechanisms linking schizophrenia and depression are polygenic. The most studied candidate genes are GRIN1 , GPM6A , SEPTIN4 , TPH1 , TPH2 , CACNA1C , CACNB2 , and BCL9. Conclusion : Planning and conducting genome-wide and associative genetic studies of the comorbid conditions under consideration in psychiatry is important for the development of biological and clinical predictors and a personalized therapy strategy for schizophrenia. However, it should be recognized that the problems of predictive and personalized psychiatry in the diagnosis and treatment of schizophrenia and comorbid disorders are far from being resolved.
Databáze: MEDLINE